Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia

作者：Ding Hilda^*; Hashem Hasan; Cabral Linda; Rangarajan Hemalatha; Abusin Ghada; Lazarus Hillard M; Abu Arja Rolla

来源：Pediatric Transplantation, 2017, 21(2): e12870.

DOI：10.1111/petr.12870

• acute myeloid leukemia
• azacitidine
• donor lymphocyte infusion
• Fanconi anemia
• hematopoietic cell transplant
• pediatric

HCT is the definitive therapy for patients with FA and AML. Conventional cytotoxic agents cause potential DNA damage, and currently, there is no established regimen for these patients prior to HCT. A 13-year-old male with FA and refractory AML was given azacitidine, achieved morphologic remission and underwent HCT. At 95 days after HCT, he relapsed. Azacitidine along with DLI was used as first salvage therapy. Azacitidine was overall well tolerated with minimal side effects. In patients with AML and FA, azacitidine can be considered an alternative to conventional chemotherapy.

• 出版日期2017-3